Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17494369 | 1.00 | KCNH2 (0.39) | KCNH2SCN5ATRPV1ALOX5APFEN1 | |
| SCHEMBL17494334 | 0.91 | CTSK (0.38) | TRPV1ALOX5APFEN1BRD4PIM1 | |
| SCHEMBL17494434 | 0.87 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL17494431 | 0.87 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL17494355 | 0.87 | KCNH2 (0.43) | KCNH2SCN5A | |
| SCHEMBL17494357 | 0.87 | KCNH2 (0.43) | KCNH2SCN5A | |
| SCHEMBL19200959 | 0.86 | KCNH2 (0.43) | KCNH2SCN5APIM1PIM3PIM2 | |
| SCHEMBL17494505 | 0.83 | CDK4 (0.39) | KCNH2 | |
| SCHEMBL19194888 | 0.83 | KCNH2 (0.44) | KCNH2SCN5A | |
| SCHEMBL19200461 | 0.83 | KCNH2 (0.43) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160726-B2 | Quinolone derivatives as antibacterials | NOVARTIS AG (CH) | 2018-12-25 | — | — | US | disclosed |
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | WUXI APPTEC (CN) | 2017-08-03 | — | — | US | disclosed |
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | WUXI APPTEC (CN) | 2017-08-03 | — | — | US | disclosed |
| EP-3177593-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | Novartis AG (CH) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016020836-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | NOVARTIS AG (CH) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | TOP1, NQO2, TOP2A | KCNH2 3467/4885SCN5A 1288/4885TRPV1 4423/4885 |
| US-10160726-B2 | Quinolone derivatives as antibacterials | TOP1, NQO2, TOP2A | KCNH2 3467/4885SCN5A 1288/4885TRPV1 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.